Compared with doxorubicin-loaded drug-eluting embolic transarterial chemoembolization (DEE-TACE), conventional transarterial chemoembolization (cTACE) yielded a higher number of quality-adjusted life years (QALY) at a lower...
Research presented in February at the Symposium on Clinical Interventional Oncology (CIO), held in conjunction with International Symposium on Endovascular Therapy (ISET), in Hollywood, USA, provides a clear shot in the arm for chemoembolization that uses doxorubicin and ethiodised oil over the triple-drug version.
While emphasising the interesting findings from their laboratory for interventional radiologists, Olivier Jordan and Katrin Fuchs write that laboratory benches not only give birth to inventions with a potential for translation into clinics, but also contribute to unbiased characterisation of products already in clinical use.
There are many new directions for research in the field of transarterial chemoembolization (TACE). After the key development of drug-eluting beads, a better understanding of the cellular mechanisms of TACE is mandatory to take the procedure further, writes Alban Denys.
David N Tran, UCSF, San Francisco, USA, spoke on the topic of chemoembolization at the Society of Interventional Radiology‰Ûªs Annual Meeting (13‰öÕ18 April 2013, New Orleans, USA), he discussed transcatheter arterial chemoembolization in liver transplant candidates with and without marginal hepatic reserve.
This advertorial is sponsored by Terumo Interventional Systems
LifePearl™ microspheres (Terumo) are polyethylene glycol (PEG) embolization microspheres that can be loaded with chemotherapeutic drugs including...
Thierry De Baère (Gustave Roussy; Villejuif, France) talks to Interventional News about the rationale behind setting up the Initiative on Superselective Conventional Transarterial Chemoembolization (INSPIRE), which...
This advertorial is sponsored by PharmaCept.
The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) recently incorporated transarterial chemoembolization with degradable starch microspheres (DSM-TACE) into...
This article is sponsored by Guerbet. immunotherapy
Preliminary evidence suggests that combining conventional transarterial chemoembolization (cTACE) with immunotherapy could be beneficial to patients with unresectable...
According to recent research from Reto Bale and colleagues, multi-probe stereotactic radiofrequency ablation with intraprocedural image fusion represents an efficient invasive therapy for hepatocellular...
Multi-probe stereotactic radiofrequency ablation (SRFA) with intraprocedural image fusion represents an efficient minimally invasive therapy for hepatocellular carcinoma (HCC), even with tumour sizes larger...
Radiation segmentectomy is a minimally invasive option that uses the radioisotope yttrium-90 (Y90) to destroy tumours. One-, three-, and five-year overall survival probability was 100%, 82% and 75% in patients with a baseline tumour size of 3cm or less.
“While both radial and femoral accesses are safe and effective for transarterial liver embolization, it is clear that the patients prefer radial access,” said Marcelo Guimaraes, Charleston, USA, who was presenting on the...
Guerbet has announced obtaining the CE mark for its conventional transarterial chemoembolization (cTACE) mixing and injection system, Vectorio.
Designed in collaboration with interventional radiologists worldwide,...
A randomised, double-blind, placebo-controlled trial evaluating the efficacy of prophylactic dexamethasone in preventing the most frequent adverse events of transcatheter arterial chemoembolization (TACE) in...
Highlights: -Immunotherapy could transform systemic power of locoregional IO treatments -Randomised data favour Y-90 therapy over conventional chemoembolization in patients with unresectable hepatocellular carcinoma...
What if physicians could perform an optical biopsy? Further, what if during a cryoablation procedure, an interventional radiologist can actually see what happens during the procedure at a cellular level in real time? A new tool, Cellvizio (Mauna Kea) does just that.
The results from a small prospective, randomised single-centre trial, the PREMIERE trial, show that in patients with unresectable hepatocellular carcinoma, there is a significantly longer time to progression with yttrium-90 (Y-90) radioembolization than with conventional transarterial chemoembolization (cTACE).
The UK National Institute for Health and Care Excellence (NICE) has issued a new Medtech Innovation Briefing stating that National Health Service doctors and commissioners may consider SIR-Spheres Y-90 resin microspheres as an alternative to standard therapy with transarterial chemoembolization or sorafenib in the treatment of patients with inoperable primary liver cancer.
Jens Ricke, professor of Radiology at the University of Magdeburg, has announced that the palliative cohort of the pan-European SORAMIC study he co-directs with Peter Malfertheiner has reached its enrolment target of 420 patients with unresectable hepatocellular carcinoma.
The final results from a phase 2 randomised trial, published online in the Journal of Clinical Oncology on 1 February, find no benefit from using doxorubicin-eluting beads (LC Bead, BTG) over embolic microspheres that do not elute a drug (Bead Block, BTG).
Early research on a simple method to produce radiopaque drug-eluting microspheres that can be incorporated into the current clinical transcatheter arterial chemoembolization workflow has also been reported.
Jafar Golzarian, a professor of interventional radiology, University of Minnesota, Minneapolis, USA, founded EmboMedics in 2012 and serves as its chief medical officer. He tells Interventional News about the factors driving an interest in resorbable embolics.
Assessment of tumour response with imaging-based tumour-specific response criteria is a crucial step to identify the value of a new therapy and to help clinicians to predict the prognosis of an individual patient, writes Christoph Zech.
A new European‰Ûwide observational study to prospectively gather data on patients treated with irinotecan‰Ûloaded microspheres has been launched by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). The CIRSE Registry for LifePearl microspheres (CIREL) will begin early in 2016.
While there is a trend towards using smaller sized particles to obtain better results with embolization, experts at the Global Embolization Symposium and Technologies (GEST EU) agreed that there appeared to be a lower size limit, <100åµm, below which drug-eluting beads did not have an effective embolic effect.
Terumo has announced that on 16 March 2015 it received CE mark for LifePearl, a new drug-eluting microsphere for chemoembolization and HydroPearl, a new microsphere for more predictable bland embolization.
A single-centre review of the safety and feasibility of using the transradial approach for peripheral and visceral interventions after the first 1,000 procedures finds that this access has extremely low complication rates.
The results of a web-based survey designed to shed light on the practice of transarterial chemoembolization (TACE) in the UK have shown that there is a wide variation in practice with some centres using conventional TACE (with lipiodol and doxorubicin) and others using, newer drug-eluting beads.
Embolization therapy combined with infusion of antineoplastic agents offers considerable improvement of symptoms for patients, with far fewer complications than systemic chemotherapy, writes Shinichi Hori, Osaka, Japan.
The Society of Interventional Radiology (SIR) has issued a global call for scientific abstracts covering all areas of vascular and nonvascular interventional radiology for its 40th Annual Scientific Meeting, which will be held 28 February‰ÛÒ5 March at the Georgia World Congress Center in Atlanta, USA.
EmboCoh is a structured international web-based channel, designed so that physicians can enter their data on embolization procedures. It will enable collaborative registry-style data collection and analysis, particularly of uncommon embolization procedures, which would not be meaningfully possible from single-centre data due to the paucity of cases.
A review, published in the Journal of Vascular and Interventional Radiology (JVIR) in August 2013, serves as an introduction to personalised oncology concepts and provides a summary of relevant concepts. Nadine Abi-Jaoudeh, lead author on the paper spoke to Interventional News about the implications for interventional radiologists.
It is now possible for members and non-members to submit abstracts online for the Society of Interventional Radiology‰Ûªs (SIR‰Ûªs) annual scientific meeting, to be held 22‰ÛÒ27 March 2014 in San Diego, USA.
Launched by the Assistance Publique Hôpitaux de Paris, France, in December 2011, SARAH (Sorafenib versus radioembolization in advanced hepatocellular carcinoma), a French national collaborative randomised controlled trial...
Investigators from Thomas Jefferson University published a study in the February edition of the Journal of Vascular and Interventional Radiology comparing the incidence of progression of hepatocellular carcinoma when treated with either doxorubicin-eluting beads or ethiodol-based regimens using either cisplatin/adriamycin/mitomycin-c (CAM) or adriamycin alone. Daniel B Brown writes about the outcomes and implications of this study.
The Surefire Infusion System ST/LT and the Surefire Specialty Catheters have received the CE mark and regulatory approval in New Zealand where distribution will begin, according to the company. The infusion system and catheters have received US FDA approval.
Michael C Soulen professor of Radiology and Surgery at Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA, and chairman of the WCIO Board of Directors discusses the recurring theme of alternative embolotherapies for hepatic malignancies
Daniel Brown, professor of Radiology, chair of the IO Central committee, describes the main features of IO-Central.org, a site designed to provide evidence-based content with real-time updates in interventional oncology.
Jon Moss, Glasgow, UK, delivered the CIRSE 2011 Andreas Gruentzig lecture. He advocated greater clinical judgement and warned that there was a ‰ÛÏring of fire‰Û in interventional radiology with several procedures being carried out without strong evidence backing them.
An SIR session titled "The Sterile Gloves Are Off" featured a heated debate on the proposition "The level of evidence linking chronic cerebrospinal venous insuffiency (CCSVI) and multiple sclerosis is inadequate and the clinical benefits of endovascular treatment are suspect"
At the CIRSE meeting 2008, held in Copenhagen, Denmark, Professors Johannes Lammer, Anthony Watkinson, and Riccardo Lencioni presented new data supporting the use of Biocompatibles‰Ûª PRECISION TACE with DC Bead (DC Bead loaded with doxorubicin) for the treatment of hepatocellular carcinoma (HCC). The multi-centre study compared drug-eluting beads (DEB) with conventional transarterial chemoembolization (cTACE).